Högskolan Dalarnas logga och länk till högskolans webbplats

du.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • chicago-author-date
  • chicago-note-bibliography
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Visual functioning and health-related quality of life in diabetic patients about to undergo anti-vascular endothelial growth factor treatment for sight-threatening macular edema
Högskolan Dalarna, Akademin Utbildning, hälsa och samhälle, Omvårdnad.ORCID-id: 0000-0001-7721-8794
Högskolan Dalarna, Akademin Utbildning, hälsa och samhälle, Omvårdnad.ORCID-id: 0000-0002-5892-9897
Högskolan Dalarna, Akademin Utbildning, hälsa och samhälle, Omvårdnad.ORCID-id: 0000-0001-8682-2045
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: Journal of diabetes and its complications, ISSN 1056-8727, E-ISSN 1873-460X, Vol. 29, nr 8, s. 1183-1190Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Purpose

To examine patient-reported outcome (PRO) in a selected group of Swedish patients about to receive anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME).

Material and methods

In this cross-sectional study, 59 patients with diabetes mellitus, who regularly visited the outpatient eye-clinics, were included. Sociodemographic and clinical data were collected and the patients completed PRO measures before starting anti-VEGF treatment. PRO measures assessed eye-specific outcomes (NEI-VFQ-25) and generic health-related quality of life (SF-36).

Results

The participants consisted of 30 men and 29 women (mean age, 68.5 years); 54 (92 %) patients had type 2 diabetes; Five (9%) patients had moderate or severe visual impairment; 28 (47 %) were classified as having mild visual impairment. Some of the patients reported overall problems in their daily lives, such as with social relationships, as well as problems with impaired sight as a result of reduced distance vision.

Conclusions

Further studies are needed to investigate PRO factors related to low perceived general health in this patient population. It is important to increase our understanding of such underlying mechanisms to promote improvements in the quality of patient care.

Ort, förlag, år, upplaga, sidor
2015. Vol. 29, nr 8, s. 1183-1190
Nyckelord [en]
Patient-reported measurements; health-related quality of life; visual function; diabetic macula edema; anti-VEGF treatment
Nationell ämneskategori
Endokrinologi och diabetes
Forskningsämne
Forskningsprofiler 2009-2020, Hälsa och välfärd
Identifikatorer
URN: urn:nbn:se:du-19091DOI: 10.1016/j.jdiacomp.2015.07.026ISI: 000366884900036PubMedID: 26318959Scopus ID: 2-s2.0-84947611604OAI: oai:DiVA.org:du-19091DiVA, id: diva2:848524
Tillgänglig från: 2015-08-25 Skapad: 2015-08-25 Senast uppdaterad: 2021-11-12Bibliografiskt granskad
Ingår i avhandling
1. Anti-VEGF treatment of patients with diabetic macular edema: Studies of visual acuity, macular edema and patient-reported outcomes
Öppna denna publikation i ny flik eller fönster >>Anti-VEGF treatment of patients with diabetic macular edema: Studies of visual acuity, macular edema and patient-reported outcomes
2016 (Engelska)Licentiatavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

The aim of this thesis was to describe and evaluate visual acuity, macular edema and patientreported outcomes (PRO) following anti-VEGF treatment of diabetic macular edema (DME) patients in a real-world setting. Using a longitudinal study design, a cohort of DME patients was followed from baseline to 1 year after treatment start. Data were collected from two eye clinics at two county hospitals. Social background characteristics, medical data and PRO were measured before treatment initiation, at four month and after 1 year. A total of 57 patients completed the study. Mean age was 69 years and the sample was equally distributed regarding sex. At baseline, the patients described their general health as low. One year after treatment initiation, 30 patients had improved visual acuity and 27 patients had no improvement in visual acuity. The patients whose visual acuity improved reported an improvement in several subscales in patient-reported outcome measures (PROM), which was in contrast to the group that experienced a decline in visual acuity, where there was no improvement in PROM. Outcomes from the study can be useful for developing and providing relevant information and support to patients undergoing this treatment.

Ort, förlag, år, upplaga, sidor
Uppsala: Uppsala universitet, 2016. s. 38
Nationell ämneskategori
Endokrinologi och diabetes
Forskningsämne
Forskningsprofiler 2009-2020, Hälsa och välfärd
Identifikatorer
urn:nbn:se:du-22715 (URN)
Handledare
Tillgänglig från: 2016-08-18 Skapad: 2016-08-18 Senast uppdaterad: 2021-11-12Bibliografiskt granskad
2. Patient-reported and medical outcomes in patients treated for diabetic macular edema: A real-world longitudinal study
Öppna denna publikation i ny flik eller fönster >>Patient-reported and medical outcomes in patients treated for diabetic macular edema: A real-world longitudinal study
2020 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Background Diabetes mellitus can lead to complications, when the complication affects the eyes it is called retinopathy. This can affect the macula and lead to severe loss of vision, diabetic macular edema (DME). This condition has traditionally been treated with laser. However, in 2011, anti-vascular endothelial growth factor (anti-VEGF) injections in the eye were approved as a treatment for diabetic macular edema, and started to be used in eye clinics.

Aim The overall aim of this thesis was to describe patient-reported outcomes and medical outcomes (PRO) in people treated for diabetic macular edema in a real-world setting in a long-time follow-up study in Sweden.

Methods Participants were enrolled at two eye clinics at two county hospitals in Sweden between 2012 and 2014. Patient-reported outcomes were measured using a vision-specific questionnaire, the 25-question National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) and a generic questionnaire, the Short Form-36 Health Survey (SF-36). Completed questionnaires, medical data such as visual acuity (EDRS), macula swelling (OCT) and social background characteristics were collected before treatment start, at one-year and four-year follow up points. The data was analyzed, descriptive statistics developed and comparative analyses were performed. Interviews were performed before treatment start and were analyzed using qualitative content analysis.

Results A total of 59 participants were included at baseline. The mean age was 69 years, with an equal gender distribution. At baseline, the participants scored a low general health with the vision-specific questionnaire. In total, 21 participants were interviewed, and a theme emerged of ‘being at a crossroads and a crucial phase in life with an uncertain outcome’. The participants expressed thoughts and concerns at different levels, including practical concerns about the treatment procedure and more existential thoughts about hope for improved visual acuity or fear of deterioration. The results at the one-year follow up showed that 30 patients had improved visual acuity and reported an improvement in several subscales in the NEI VFQ-25. The remaining 27 participants had no improvement in visual acuity or in the vision specific questionnaire. The four-year follow-up involved 37 people, and the result showed significant improvement in subjective near-vision activities and improved distance visual acuity.

Conclusion: Before treatment, the participants reported low general health and expressed concerns about the injection treatment and their vision. One year after treatment started, the results showed significant improvement in several NEI VFQ-25 subscales, decreased macula swelling and improved visual acuity. These positive results remained at the four-year follow-up point.

Ort, förlag, år, upplaga, sidor
Uppsala: Acta Universitatis Upsaliensis, 2020. s. 68
Nyckelord
Diabetes mellitus, Patient-reported outcomes, Retinopathy, Macular edema, Anti-VEGF treatment
Nationell ämneskategori
Endokrinologi och diabetes
Forskningsämne
Forskningsprofiler 2009-2020, Hälsa och välfärd
Identifikatorer
urn:nbn:se:du-32652 (URN)978-91-513-0896-8 (ISBN)
Disputation
2020-04-28, Aula Gunnesalen, Ingång 10, Psykiatrins hus. Akademiska sjukhuset Uppsala., 13:00 (Svenska)
Opponent
Handledare
Tillgänglig från: 2020-05-11 Skapad: 2020-05-11 Senast uppdaterad: 2021-11-12Bibliografiskt granskad

Open Access i DiVA

fulltext(1018 kB)298 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1018 kBChecksumma SHA-512
8434e429c109fb9f4484b73c355f7adc946dfeb9a292ff1d7c42754da6b60a4f5d7b9a8ad19fb13deeb39d7dd2c70da754178cf8bcb15ae8157a3053eb16418f
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Granström, ThereseForsman, HenriettaLeksell, Janeth

Sök vidare i DiVA

Av författaren/redaktören
Granström, ThereseForsman, HenriettaLeksell, Janeth
Av organisationen
Omvårdnad
I samma tidskrift
Journal of diabetes and its complications
Endokrinologi och diabetes

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 298 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 740 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • chicago-author-date
  • chicago-note-bibliography
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf